Jarrod Longcor
Geschäftsführer bei CELLECTAR BIOSCIENCES, INC.
Vermögen: 160 486 $ am 30.04.2024
Profil
Jarrod Longcor is currently the Chief Operating Officer at Cellectar Biosciences, Inc. He previously held positions as the Senior Director of Business Development at Middlebrook Pharmaceuticals, Inc., the Director of Business Development at MaxCyte, Inc., the Vice President of Corporate Development at Melinta Subsidiary Corp., and the Chief Business Officer at Avillion LLP.
Mr. Longcor received his undergraduate degree from Dickinson College, his graduate degree from Boston University School of Medicine, and his MBA from Erivan K.
Haub School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 24.04.2024 | 53 141 ( 0,15% ) | 160 486 $ | 30.04.2024 |
Aktive Positionen von Jarrod Longcor
| Unternehmen | Position | Beginn |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Geschäftsführer | 23.02.2022 |
Ehemalige bekannte Positionen von Jarrod Longcor
| Unternehmen | Position | Ende |
|---|---|---|
Avillion LLP
 Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01.07.2016 |
Melinta Subsidiary Corp.
 Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Corporate Officer/Principal | 01.09.2013 |
| MAXCYTE, INC. | Corporate Officer/Principal | - |
Middlebrook Pharmaceuticals, Inc.
 Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Corporate Officer/Principal | - |
Ausbildung von Jarrod Longcor
| Dickinson College | Undergraduate Degree |
| Erivan K. Haub School of Business | Masters Business Admin |
| Boston University School of Medicine | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MAXCYTE, INC. | Health Technology |
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
Middlebrook Pharmaceuticals, Inc.
Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Health Technology |
Avillion LLP
Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Health Technology |
